Fulcrum Therapeutics (FULC) Competitors

$7.11 -0.14 (-1.93%)

Closing price 04:00 PM Eastern

Extended Trading

$7.10 -0.02 (-0.21%)

As of 04:10 PM Eastern

FULC vs. SION, QURE, CAPR, SNDX, and LKFT

Should you buy Fulcrum Therapeutics stock or one of its competitors? MarketBeat compares Fulcrum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulcrum Therapeutics include Sionna Therapeutics (SION), uniQure (QURE), Capricor Therapeutics (CAPR), Syndax Pharmaceuticals (SNDX), and Lakefront Biotherapeutics American Depositary Shares (LKFT). These companies are all part of the "pharmaceutical products" industry.

How does Fulcrum Therapeutics compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Sionna Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market.

Sionna Therapeutics' return on equity of -26.60% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-26.60%	-25.23%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 3.9% of Sionna Therapeutics shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sionna Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A

Sionna Therapeutics currently has a consensus target price of $53.00, suggesting a potential upside of 23.92%. Fulcrum Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 167.23%. Given Fulcrum Therapeutics' higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sionna Therapeutics had 21 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 24 mentions for Sionna Therapeutics and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.83 beat Sionna Therapeutics' score of -0.15 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulcrum Therapeutics beats Sionna Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to uniQure?

Fulcrum Therapeutics (NASDAQ:FULC) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, uniQure had 11 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 14 mentions for uniQure and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.83 beat uniQure's score of 0.52 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulcrum Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market. Comparatively, uniQure has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Fulcrum Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 167.23%. uniQure has a consensus price target of $42.83, suggesting a potential upside of 54.35%. Given Fulcrum Therapeutics' higher possible upside, equities research analysts clearly believe Fulcrum Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Fulcrum Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Fulcrum Therapeutics' return on equity of -27.80% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
uniQure	-1,154.42%	-145.81%	-27.15%

Fulcrum Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A
uniQure	$18.09M	96.73	-$198.97M	-$3.48	N/A

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Fulcrum Therapeutics beats uniQure on 11 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Capricor Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Capricor Therapeutics had 17 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 20 mentions for Capricor Therapeutics and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.83 beat Capricor Therapeutics' score of 0.12 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Capricor Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.32	N/A

Fulcrum Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Fulcrum Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 167.23%. Capricor Therapeutics has a consensus price target of $46.09, suggesting a potential upside of 54.62%. Given Fulcrum Therapeutics' higher possible upside, equities research analysts clearly believe Fulcrum Therapeutics is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Fulcrum Therapeutics' return on equity of -27.80% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Capricor Therapeutics	N/A	-69.50%	-55.81%

Summary

Fulcrum Therapeutics beats Capricor Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Syndax Pharmaceuticals?

Fulcrum Therapeutics (NASDAQ:FULC) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Fulcrum Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.83 beat Syndax Pharmaceuticals' score of 0.05 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fulcrum Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 167.23%. Syndax Pharmaceuticals has a consensus price target of $42.55, suggesting a potential upside of 107.03%. Given Fulcrum Therapeutics' higher probable upside, equities analysts plainly believe Fulcrum Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Fulcrum Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Fulcrum Therapeutics' return on equity of -27.80% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Fulcrum Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A
Syndax Pharmaceuticals	$217.17M	8.38	-$285.42M	-$2.79	N/A

Summary

Fulcrum Therapeutics beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 3 articles in the media. Fulcrum Therapeutics' average media sentiment score of 0.83 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.14 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fulcrum Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.74	$363.05M	-$1.41	N/A
Fulcrum Therapeutics	N/A	N/A	-$74.88M	-$1.15	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $36.50, indicating a potential upside of 32.78%. Fulcrum Therapeutics has a consensus price target of $19.00, indicating a potential upside of 167.23%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Fulcrum Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 14 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$473.76M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-6.18	18.81	20.87	25.58
Price / Sales	N/A	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.42	6.74	9.86	6.70
Net Income	-$74.88M	$24.11M	$3.55B	$333.77M
7 Day Performance	3.34%	0.07%	-0.32%	0.45%
1 Month Performance	-10.23%	0.84%	1.34%	4.06%
1 Year Performance	26.29%	78.10%	41.03%	36.21%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	1.8684 of 5 stars	$7.11 -1.9%	$19.00 +167.2%	+25.2%	$473.76M	N/A	N/A	100
SION Sionna Therapeutics	1.8736 of 5 stars	$41.01 -10.8%	$53.00 +29.2%	+236.3%	$1.86B	N/A	N/A	35	Earnings Report Analyst Forecast Insider Trade
QURE uniQure	2.9275 of 5 stars	$29.00 +4.9%	$42.83 +47.7%	+127.7%	$1.83B	$16.10M	N/A	500	Insider Trade
CAPR Capricor Therapeutics	2.2948 of 5 stars	$31.54 -1.1%	$46.09 +46.2%	+315.5%	$1.82B	$22.27M	N/A	101	Earnings Report Analyst Forecast
SNDX Syndax Pharmaceuticals	2.9527 of 5 stars	$20.53 -4.0%	$42.64 +107.7%	+105.0%	$1.82B	$172.35M	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SION, QURE, CAPR, SNDX, and LKFT

How does Fulcrum Therapeutics compare to Sionna Therapeutics?

Summary

How does Fulcrum Therapeutics compare to uniQure?

Summary

How does Fulcrum Therapeutics compare to Capricor Therapeutics?

Summary

How does Fulcrum Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Fulcrum Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SION, QURE, CAPR, SNDX, and LKFT

How does Fulcrum Therapeutics compare to Sionna Therapeutics?

Which has more volatility and risk, SION or FULC?

Is SION or FULC more profitable?

Do institutionals & insiders have more ownership in SION or FULC?

Which has preferable earnings & valuation, SION or FULC?

Do analysts recommend SION or FULC?

Does the media prefer SION or FULC?

Summary

How does Fulcrum Therapeutics compare to uniQure?

Does the media favor FULC or QURE?

Which has more risk & volatility, FULC or QURE?

Do analysts prefer FULC or QURE?

Is FULC or QURE more profitable?

Which has stronger earnings & valuation, FULC or QURE?

Do institutionals and insiders have more ownership in FULC or QURE?

Summary

How does Fulcrum Therapeutics compare to Capricor Therapeutics?

Does the media favor FULC or CAPR?

Which has stronger earnings & valuation, FULC or CAPR?

Which has more risk & volatility, FULC or CAPR?

Do institutionals and insiders have more ownership in FULC or CAPR?

Do analysts prefer FULC or CAPR?

Is FULC or CAPR more profitable?

Summary

How does Fulcrum Therapeutics compare to Syndax Pharmaceuticals?

Which has more risk and volatility, FULC or SNDX?

Does the media refer more to FULC or SNDX?

Do institutionals & insiders hold more shares of FULC or SNDX?

Do analysts prefer FULC or SNDX?

Is FULC or SNDX more profitable?

Which has stronger valuation & earnings, FULC or SNDX?

Summary

How does Fulcrum Therapeutics compare to Lakefront Biotherapeutics American Depositary Shares?

Does the media prefer LKFT or FULC?

Which has more risk and volatility, LKFT or FULC?

Which has preferable valuation & earnings, LKFT or FULC?

Is LKFT or FULC more profitable?

Do analysts recommend LKFT or FULC?

Do insiders and institutionals hold more shares of LKFT or FULC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools